Acceleron announces topline results from the phase II trial of ACE 083 in patients with Charcot-Marie-Tooth disease
Read time: 1 mins
Published:11th Mar 2020
-Acceleron Pharma announced that treatment with ACE 083 in patients with Charcot-Marie-Tooth disease (CMT) did not demonstrate functional improvement in the Phase II trial. ACE 083 demonstrated a statistically significant increase in mean total muscle volume, the trial’s primary endpoint. However, the increase did not translate to statistically significant improvements in any of the functional or quality of life secondary endpoints when compared to placebo. As a result, Acceleron is discontinuing development of ACE 083.
Condition: Charcot-Marie-Tooth disease